Company Profiles

driven by the PitchBook Platform

Atreca

Atreca
2010 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$35M LATEST DEAL AMOUNT
$98.1M TOTAL AMOUNT RAISED
6 INVESTORS
Description

Developer of novel therapeutics designed to engage the human immune response in oncology and other indications. The company's Immune Repertoire Capture (IRC) and DeepSeq technologies deliver the sequences of antibodies and T cell receptors (TCRs) elaborated by informationally rich subsets of patient B and T cells with virtually no bias or error, enabling the identification and generation of functional and valuable human antibodies and TCRs directly from patients without prior knowledge of antigen.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Primary Office
500 Saginaw Drive
Redwood City, CA 94063
United States

+1 (650) 595-2595
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Atreca’s full profile, request a free trial.

Atreca Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Early Stage VC (Series B) 17-Aug-2017 $35M $98.1M 00000 Completed Product Development
7. Later Stage VC (Series A) 20-Oct-2015 0000 000.00 00000 Completed Startup
6. Early Stage VC 30-Aug-2013 00000 00.000 Completed Startup
5. Early Stage VC 25-Sep-2012 000 00.000 Completed Startup
4. Early Stage VC 19-Apr-2012 0000 00000 Completed Startup
3. Early Stage VC 02-Mar-2012 0000 00000 Completed Startup
2. Early Stage VC 29-Feb-2012 $350k $350k Completed Startup
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Atreca Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 000
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table request access »

Atreca Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
GSK Corporation Minority 000 0000 000000 0
Mission Bay Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Atreca Executive Team (11)

Name Title Board
Seat
Contact
Info
Tito Serafini Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Susan Berland Chief Financial Officer
Norman Greenberg Ph.D Chief Scientific Officer
Guy Cavet Ph.D Co-Founder & Chief Technical Officer
Nigel Ray Senior Vice President and Chief Business Officer
You’re viewing 5 of 11 executives. Get the full list »

Atreca Board Members (9)

Name Representing Role Since Contact
Info
Andrew Farnum Bill & Melinda Gates Foundation Board Observer 000 0000
Brian Atwood Self Chairman 000 0000
Brian Atwood Atreca Chairman 000 0000
David Lacey MD Self Board Member 000 0000
Douglas Crawford Ph.D Mission Bay Capital Board Observer 000 0000
You’re viewing 5 of 9 board members. Get the full list »